Trajan Scientific and Medical has finalized the acquisition of the latest addition to their portfolio, Axel Semrau GmbH & Co expanding its capabilities in the automation, chromatography, and software business.
Axel Semrau joins Trajan with 40 years of experience in the global biotechnology market and employs just over 50 staff in Europe. It designs, develops, and delivers laboratory automation and chromatography software and detection systems. Trajan’s automation business and Axel Semrau have worked in close cooperation for several years and so we enter this new stage with a working relationship already well established.
Trajan Automation's presence is weighted primarily in North America whereas Axel Semrau’s focus is in Europe. Trajan Automation's application expertise concentrates in the Pharmaceutical and Clinical segments, Axel Semrau dominates more in the Food and Environmental markets.
Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated “We welcome the Axel Semrau team to the Trajan group. Trajan’s automation business and Axel Semrau have worked in close cooperation for several years and so we enter this new stage with a working relationship already well established. Axel Semrau owns and develops the CHRONOS intelligent sequencing software platform upon which Trajan’s automated workflows are built. We intend to further invest in CHRONOS in line with Trajan’s goal to simplify and automate complex analytical workflows.”
“Further, Axel Semrau’s automation business is highly synergistic with our own; both in terms of application areas and geographical coverage. Axel Semrau’s presence in chromatography and portable/on line gas detection also aligns with Trajan’s general direction.”
This completes Trajan’s ninth acquisition to date of a private business, which also included its manufacturing and distribution facilities based in Sprockhövel Germany.
Trajan is delivering on its M&A promise made to investors and shareholders pre-IPO, and Joint Lead Manager Canaccord Genuity says that through its investments, Trajan “is gradually positioning itself to benefit from the long-term trend toward data leading to predictive and preventive personal health, coupled with early intervention where necessary.”
As Trajan continues to grow in size and capability its main purpose, Science that benefits people, continues to be front of mind. Trajan strives to work in collaboration with like-minded people to make an impact on human wellbeing.